Harrow (HROW) Non-Current Deferred Tax Liability (2015 - 2024)

Harrow (HROW) recorded quarterly Non-Current Deferred Tax Liability of $643000.0 in Q3 2024, up 3.21% quarter-over-quarter from $623000.0 in Q2 2024.

Harrow (HROW) Non-Current Deferred Tax Liability (2015 - 2024) Analysis & Trends

Harrow's Non-Current Deferred Tax Liability history runs 4 years deep, the most recent figure standing at $643000.0 for Q3 2024.

In Q3 2024, Non-Current Deferred Tax Liability changed N/A year-over-year to $643000.0; the TTM figure through Sep 2024 stood at $643000.0 (changed N/A YoY), while the FY2016 annual figure was $936000.0, down 10.6% from the prior year.
Non-Current Deferred Tax Liability was $643000.0 for Q3 2024 at Harrow, up from $623000.0 in the prior quarter.
In the past five years, Non-Current Deferred Tax Liability ranged from a high of $643000.0 in Q3 2024 to a low of $623000.0 in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Teva Pharmaceutical Industries	39.72 Bn	35.98 Bn	1.97 Bn
2	Zoetis	34.61 Bn	32.67 Bn	1.62 Bn
3	United Therapeutics	24.07 Bn	21.91 Bn	648.10 Mn
4	Aurora Cannabis	16.98 Bn	16.91 Bn	33.43 Mn
5	Neurocrine Biosciences	16.64 Bn	15.32 Bn	800.70 Mn
6	Elanco Animal Health	12.19 Bn	11.76 Bn	785.00 Mn
7	Alkermes	7.37 Bn	6.86 Bn	-116.06 Mn
8	Hims & Hers Health	6.62 Bn	5.87 Bn	396.79 Mn
9	Lantheus Holdings	6.47 Bn	5.97 Bn	230.92 Mn
10	Harrow	1.25 Bn	1.15 Bn	27.05 Mn

Download Data